Lineage Cell Therapeutics (LCTX)
(Real Time Quote from BATS)
$0.84 USD
-0.06 (-6.95%)
Updated Aug 12, 2024 03:06 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Lineage Cell Therapeutics, Inc. [LCTX]
Reports for Purchase
Showing records 81 - 99 ( 99 total )
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results: Cranking on All Pistons With More to Come
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Busy Bees at Lineage Cell; VAC2 Option Exercised From CRUK Based on Immunogenicity Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ARVO OpRegen Update Keep Things Nicely on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Straight to the Dendritic Cell Workhorse for COVID-19; Approach Makes Sense to Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; Marching Towards Key Updates Through 2020 Beginning With Dry-AMD in Early May
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Checking off Important Boxes for OpRegen Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Starting 2020 With Positive Updates and Cash Infusion
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOLs Add Fuel to Our Lineage Investment Case
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Continued Eyes on OpRegen Plus Pipeline Visibility in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive OpRegen Clinical Update and Durability Case Continues to Build; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Renevia Awarded CE Mark in E.U.; Important Validation for Rebranded Lineage
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J